Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease
Joint Authors
Scirocco, Chiara
Gubbiotti, Andreina
Sebastiani, Alfredo
Sebastiani, Gian Domenico
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-05-30
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
In this paper, we report a challenging case of a middle-age woman who developed antimelanoma differentiation-associated protein-5 dermatomyositis (anti-MDA5 DM) with interstitial lung disease (ILD) and was successfully treated with rituximab (RTX), after failure of a first-line therapy.
American Psychological Association (APA)
Scirocco, Chiara& Gubbiotti, Andreina& Sebastiani, Alfredo& Sebastiani, Gian Domenico. 2020. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1151178
Modern Language Association (MLA)
Scirocco, Chiara…[et al.]. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1151178
American Medical Association (AMA)
Scirocco, Chiara& Gubbiotti, Andreina& Sebastiani, Alfredo& Sebastiani, Gian Domenico. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1151178
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1151178
